Cargando…

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

BACKGROUND: Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM). AIM: To analyse six studies that examined eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Immunomodulators and Adalimumab for IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157781/ https://www.ncbi.nlm.nih.gov/pubmed/27883215 http://dx.doi.org/10.1111/apt.13838

Ejemplares similares

Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
por: Nakase, H., et al.
Publicado: (2017)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Exogenous IFN-γ ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3(+) regulatory T cells
por: Feng, Gang, et al.
Publicado: (2008)

Human β-defensin 3 has immunosuppressive activity in vitro and in vivo
por: Semple, Fiona, et al.
Publicado: (2010)

Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells
por: Magnani, Chiara F, et al.
Publicado: (2011)

Progesterone promotes maternal–fetal tolerance by reducing human maternal T‐cell polyfunctionality and inducing a specific cytokine profile
por: Lissauer, David, et al.
Publicado: (2015)

HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells
por: Che, Karlhans F, et al.
Publicado: (2010)

Arginine depletion as a mechanism for the immune privilege of corneal allografts
por: Fu, Hongmei, et al.
Publicado: (2011)

Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition
por: Khan, Adnan, et al.
Publicado: (2013)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity
por: Simon, Anna Katharina, et al.
Publicado: (2007)

Regulatory T cells can prevent memory CD8(+) T-cell-mediated rejection following polymorphonuclear cell depletion
por: Jones, Nick D, et al.
Publicado: (2010)

Absence of Rac1 and Rac3 GTPases in the nervous system hinders thymic, splenic and immune-competence development
por: Basso, Veronica, et al.
Publicado: (2011)

Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells
por: Francis, Ross S, et al.
Publicado: (2011)

Anti-CD4-mediated selection of Treg in vitro – in vitro suppression does not predict in vivo capacity to prevent graft rejection
por: Oliveira, Vanessa, et al.
Publicado: (2008)

Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region
por: Wooldridge, Linda, et al.
Publicado: (2007)

A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1
por: Apps, Richard, et al.
Publicado: (2007)

Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naïve T cells
por: Rossetti, Maura, et al.
Publicado: (2010)

PD-1 modulates steady-state and infection-induced IL-10 production in vivo
por: McBerry, Cortez, et al.
Publicado: (2014)

Exacerbated experimental arthritis in Wiskott–Aldrich syndrome protein deficiency: Modulatory role of regulatory B cells
por: Bouma, Gerben, et al.
Publicado: (2014)

Human β-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF
por: Semple, Fiona, et al.
Publicado: (2011)

IL-33 attenuates the development of experimental autoimmune uveitis
por: Barbour, Mark, et al.
Publicado: (2014)

Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter
por: Hill, Elaine V, et al.
Publicado: (2015)

IL‐12/15/18‐preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation
por: Hüber, Christian M., et al.
Publicado: (2015)

OX40 controls effector CD4(+) T-cell expansion, not follicular T helper cell generation in acute Listeria infection
por: Marriott, Clare L, et al.
Publicado: (2014)

HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
por: Sottile, Rosa, et al.
Publicado: (2015)

Exposure to inflammatory cytokines selectively limits GM-CSF production by induced T regulatory cells
por: Reynolds, Ben C, et al.
Publicado: (2014)

Signal regulatory protein alpha (SIRPα) regulates the homeostasis of CD103(+)CD11b(+) DCs in the intestinal lamina propria
por: Scott, Charlotte L, et al.
Publicado: (2014)

Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage
por: Schminke, Boris, et al.
Publicado: (2015)

The site of allergen expression in hematopoietic cells determines the degree and quality of tolerance induced through molecular chimerism
por: Baranyi, Ulrike, et al.
Publicado: (2013)

IL‐12 and IL‐4 activate a CD39‐dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells
por: Noble, Alistair, et al.
Publicado: (2016)

NFATc1 deficiency in T cells protects mice from experimental autoimmune encephalomyelitis
por: Reppert, Sarah, et al.
Publicado: (2015)

Non‐glycosidic compounds can stimulate both human and mouse iNKT cells
por: Jukes, John‐Paul, et al.
Publicado: (2016)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_672frq8m0acbtopcf744013p8j